Mauricette Michallet focuses on Internal medicine, Surgery, Transplantation, Gastroenterology and Leukemia. Many of her studies on Internal medicine involve topics that are commonly interrelated, such as Oncology. Mauricette Michallet focuses mostly in the field of Surgery, narrowing it down to matters related to Multiple myeloma and, in some cases, Autologous transplantation, Survival rate and Dexamethasone.
Mauricette Michallet has included themes like Cyclophosphamide, Stem cell and Immunology in her Transplantation study. Her Gastroenterology research is multidisciplinary, relying on both Busulfan, Cytarabine, Regimen, Chronic myelogenous leukemia and Hazard ratio. The Leukemia study combines topics in areas such as Myeloid, Cancer research and Marrow transplantation.
Her main research concerns Internal medicine, Transplantation, Surgery, Gastroenterology and Oncology. Her work in Hematopoietic stem cell transplantation, Myeloid leukemia, Cumulative incidence, Acute leukemia and Chemotherapy are all subfields of Internal medicine research. Her Transplantation study combines topics from a wide range of disciplines, such as Regimen, Stem cell, Immunology and Fludarabine.
Her study explores the link between Surgery and topics such as Multiple myeloma that cross with problems in Dexamethasone. Her Gastroenterology research incorporates elements of Progressive disease, Chronic myelogenous leukemia, Univariate analysis, Hazard ratio and Survival analysis. When carried out as part of a general Oncology research project, her work on Autologous stem-cell transplantation is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Oncology and Myeloid leukemia are her primary areas of study. The concepts of her Internal medicine study are interwoven with issues in Gastroenterology and Surgery. Her work carried out in the field of Transplantation brings together such families of science as Stem cell, Cell therapy, Incidence and Chronic lymphocytic leukemia.
Mauricette Michallet interconnects Survival rate, Regimen, Immunology, Histocompatibility and Fludarabine in the investigation of issues within Hematopoietic stem cell transplantation. In general Oncology study, her work on Autologous stem-cell transplantation often relates to the realm of In patient, thereby connecting several areas of interest. Her Myeloid leukemia study combines topics in areas such as Myeloid and Leukemia.
Mauricette Michallet mostly deals with Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Myeloid leukemia and Surgery. Her biological study spans a wide range of topics, including Gastroenterology and Oncology. She combines subjects such as Leukemia, Survival analysis and Hazard ratio with her study of Transplantation.
The various areas that Mauricette Michallet examines in her Hematopoietic stem cell transplantation study include Survival rate, Immunology, Histocompatibility and Chemoimmunotherapy. Her studies in Myeloid leukemia integrate themes in fields like Myeloid, Stem cell, Cord Blood Stem Cell Transplantation and Bone marrow. Mauricette Michallet interconnects Creatinine and Adverse effect in the investigation of issues within Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot.
The New England Journal of Medicine (2012)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel.
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
Guilhot F;Chastang C;Michallet M;Guerci A.
The New England Journal of Medicine (1997)
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Jean-Luc Harousseau;Michel Attal;Hervé Avet-Loiseau;Gerald Marit.
Journal of Clinical Oncology (2010)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial
Philippe Moreau;Thierry Facon;Michel Attal;Cyrille Hulin.
Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Société Française de Greffe de Moelle
Didier Blaise;Mathieu Kuentz;Cecile Fortanier;Jean Henri Bourhis.
Journal of Clinical Oncology (2000)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.
P Dreger;P Corradini;E Kimby;M Michallet.
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Frederic Garban;Michel Attal;Mauricette Michallet;Cyrille Hulin.
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres.
G. Gahrton;H. Svensson;M. Cavo;J. Apperley.
British Journal of Haematology (2001)
Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias.
D. Maraninchi;D. Blaise;B. Rio;V. Leblond.
The Lancet (1987)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: